Cerus Corporation to Participate in Upcoming Investor Conferences
February 25 2020 - 8:30AM
Business Wire
Cerus Corporation (Nasdaq:CERS) announced today that the Company
will participate in two upcoming investor conferences.
- William ‘Obi’ Greenman, Cerus’ president and chief executive
officer and Kevin D. Green, Cerus’ chief financial officer, are
scheduled to present a corporate update at the Cowen and Company
40th Annual Healthcare Conference in Boston on Tuesday, March 3rd
at 8:00 A.M. ET.
- Kevin D. Green is scheduled to participate in the BTIG Medtech,
Digital Health, Life Science & Diagnostic Tools Conference 2020
in Snowbird on Wednesday, March 18th.
A live webcast of the presentation from Cowen’s 40th Annual
Healthcare Conference will be available on the Investor Relations
page of the Cerus web site at http://www.cerus.com/ir. A replay
will be available for approximately two weeks following the
completion of the event.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Based in Concord, California, our employees are
dedicated to deploying and supplying vital technologies and
pathogen-protected blood components for blood centers, hospitals
and ultimately patients who rely on safe blood. With the INTERCEPT
Blood System, we are focused on protecting patients by delivering
the full complement of reliable products and expertise for
transfusion medicine. Cerus develops and markets the INTERCEPT
Blood System, and remains the only company in the blood transfusion
space to earn both CE Mark and FDA approval for pathogen reduction
of both platelet and plasma components. Cerus currently markets and
sells the INTERCEPT Blood System in the United States, Europe, the
Commonwealth of Independent States, the Middle East and selected
countries in other regions around the world. The INTERCEPT Red
Blood Cell system is in clinical development. For more information
about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200225005370/en/
Tim Lee – Investor Relations Director Cerus Corporation
925-288-6137
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Sep 2023 to Sep 2024